Sacituzumab govitecan-hziy clinical trials
6 indexed studies · 2 currently recruiting
- Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
This study looks at a new drug, sacituzumab govitecan, for women with endometrial cancer that has come back or hasn't responded to earlier treatments. It compares this new drug to standard treatments chosen by doctors, aiming to see if it helps women live longer or keeps cancer from growing.
For: Endometrial CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study looks at a new drug, Sacituzumab Govitecan-hziy, for people with an aggressive type of breast cancer called triple-negative breast cancer that has spread or can't be operated on. It compares this new drug to standard treatments to see which works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 NegativeUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 PositiveUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
For: Locally Advanced or Unresectable Metastatic Breast Cancer · Stage IV Breast CancerUnited States · Argentina · Australia - RecruitingPHASE1
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
This study is looking into a new treatment called sacituzumab govitecan for people with advanced cancer and some liver problems. It aims to find the safest dose and understand its effects in this group of patients.
For: Advanced or Metastatic Solid Tumor · Liver FailureUnited States · France · Italy - RecruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany